Physician profile
Agha Raza
NPI 1790851939
$2,435.72
in general payments reported to CMS, 2019-2025
37 companies · $64.34 in 2025
The $64.34 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $153 · 2021: $481 · 2022: $597 · 2023: $364 · 2024: $31.22 · 2025: $64.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.67 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $374.37 | 2019-2020 | |
| Boston Scientific Corporation | $133.55 | 2023 | Watchman Flx |
| Ucb, INC. | $117.83 | 2019-2022 | |
| Allergan, INC. | $106.39 | 2019-2022 | |
| Eisai INC. | $105.65 | 2021-2023 | |
| Novo Nordisk INC | $99.91 | 2023 | Ozempic |
| Adamas Pharmaceuticals, INC. | $90.39 | 2019-2021 | |
| Lundbeck LLC | $84.76 | 2021-2023 | Vyepti |
| Arbor Pharmaceuticals, INC. | $69.61 | 2019-2021 | |
| Amgen INC. | $61.82 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $59.91 | 2022 | |
| Argenx US, INC. | $48.56 | 2022-2023 | Vyvgart |
| Biohaven Pharmaceuticals, INC. | $47.64 | 2021 | |
| Avanir Pharmaceuticals, INC. | $47.33 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $42.23 | 2021-2022 | |
| Ge Healthcare | $40.93 | 2019 | |
| Grifols USA, LLC | $37.55 | 2019 | |
| Amneal Pharmaceuticals LLC | $36.23 | 2019 | |
| Neurocrine Biosciences, INC. | $32.44 | 2022 | |
| Alexion Pharmaceuticals, INC. | $30.09 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $26.52 | 2021-2023 | Nuplazid |
| Kyowa Kirin, INC. | $25.21 | 2022 | |
| Alnylam Pharmaceuticals INC. | $24.43 | 2021 | |
| Pfizer INC. | $22.47 | 2021 | |
| Tanabe Pharma America, INC. | $19.45 | 2022 | |
| Upsher-Smith Laboratories LLC | $17.95 | 2019 | |
| Shire North American Group INC | $16.98 | 2019 | |
| Emd Serono, INC. | $16.94 | 2022 | |
| Neurelis, INC. | $16.90 | 2022 | |
| Acorda Therapeutics, INC | $14.61 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.52 | 2020 | |
| Currax Pharmaceuticals LLC | $14.20 | 2020 | |
| Scilex Pharmaceuticals INC. | $13.04 | 2019 | |
| Lilly USA, LLC | $12.65 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.01 | 2019 | |
| Medtronic USA, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Agha Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.